About Regeneron Ventures
Regeneron Ventures is a venture capital firm founded in 2024. It is primarily based out of Tarrytown, United States. As of Jun 2026, Regeneron Ventures is an active investor, having invested in 14 companies, with 7 new investments in the last 12 months. It primarily invests in Series B round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and Enterprise Applications. Most recently it participated in the $***** Series B round of City Therapeutics A lot of funds co-invest with Regeneron Ventures, with names like Invus sharing a substantial percentage of its portfolio. Regeneron Ventures has team of 2 people including 2 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series B, Series A & 1 more
Portfolio Soonicorns
Deals in last 12 months
Regeneron Ventures' List of Top Investments
Regeneron Ventures has a portfolio of 14 companies. Their most notable investments are in ArsenalBio and Actio Biosciences.Their portfolio spans across United States and Belgium. They have invested in Life Sciences, High Tech, Enterprise Applications and 1 other sectors, across stages such as Series B, Series A and 1 more. Here is the list of top investments by Regeneron Ventures:
Provider of a platform to deliver mRNA therapeutics for multi-functional treatments. The programming platform detects the location and enhances the cell type protein expression in the patient's body to optimize the immunotherapy treatments.
Key facts about Strand Therapeutics
- Founded Year: 2017
- Location: Cambridge (United States)
- Stage: Series B
- Total Funding till date: $256M
- Employee Count: 121 as on May 31, 2026
- Investors: Kinnevik, Redmile Group and 19 Others
- Latest Funding Round: Series B, May 23, 2025, $*****
- Highlight: Editors' Pick
2. ArsenalBio
Developer of immune cell therapies for cancer treatment. It develops programmable immune cell therapies using cloud computing, genome engineering, and synthetic immunology technologies. It offers a pipeline of drug candidates which include AB-2100 for kidney cancer, and AB-3000 targeted at prostate cancer.
Key facts about ArsenalBio
- Founded Year: 2019
- Location: San Francisco (United States)
- Stage: Series C
- Total Funding till date: $631M
- Employee Count: 186 as on May 31, 2026
- Investors: T. Rowe Price, Sixth Street and 22 Others
- Latest Funding Round: Series C, Jul 09, 2024, $*****
- Highlight: Editors' Pick
Developer of cell and gene therapy by using the epigenomic platform. The company has an epigenome editing and gene regulation platform to develop therapeutics for complex diseases without altering the DNA sequence.
Key facts about Tune Therapeutics
- Founded Year: 2009
- Location: Seattle (United States)
- Stage: Series B
- Total Funding till date: $222M
- Employee Count: 69 as on May 31, 2026
- Investors: New Enterprise Associates, Emerson Collective and 8 Others
- Latest Funding Round: Series B, Mar 09, 2023, $*****
- Highlight: Editors' Pick
Developer of gene therapies for multiple diseases. It offers RNAi therapeutics based on next-generation engineering of small interfering RNAs for patients across multiple disease indications.
Key facts about City Therapeutics
- Founded Year: 2006
- Location: Cambridge (United States)
- Stage: Series B
- Total Funding till date: $234M
- Employee Count: 78 as on May 31, 2026
- Investors: Fidelity Investments, Invus and 9 Others
- Latest Funding Round: Series B, Jun 08, 2026, $*****
- Highlight: Editors' Pick
Provider of synthetic biology platform to develop small-molecule therapeutics. The company's platform combines applied microbiology, enzymology, and data science to develop medicines against difficult-to-drug proteins.
Key facts about Think Bioscience
- Founded Year: 2019
- Location: Boulder (United States)
- Stage: Series A
- Total Funding till date: $26M
- Employee Count: 31 as on May 31, 2026
- Investors: Janus Henderson Investors, Crescent Enterprises and 12 Others
- Latest Funding Round: Series A, Jan 20, 2026, $*****
- Highlight: Editors' Pick
Regeneron Ventures' Year-on-Year Investment Trends
Regeneron Ventures has invested in 14 companies over the last 3 years, with an average of 4 new investments annually in the last 3 years. In 2025, it made 7 investments, while as of Jun 2026, it has made 4 investments in this year. Its most recent first time investment was in Coultreon and most recent follow-on round was in City Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 3 | 1 | 4 |
2025 | 7 | 0 | 7 |
2024 | 3 | 0 | 3 |
2023 | 1 | 0 | 1 |
Regeneron Ventures' Investments by Stage
Regeneron Ventures has made 7 investments in Series B stage with an average round size of $117M, 5 investments in Series A stage with an average round size of $89.4M and 2 investments in Series C stage with an average round size of $213M.Stage of entry | No. of Investments |
|---|---|
Series B | 7 |
Series A | 5 |
Series C | 2 |
Note: We have considered here, only first round of investments
Regeneron Ventures' Investments by Sector
Regeneron Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Artificial Intelligence - Industry Applications. Notably, it has invested in 14 Tech companies, 13 Enterprise (B2B) companies, 3 Software companies and at least 1 company focusing on AI-Native.Sector | No. of Investments |
|---|---|
Life Sciences | 14 |
High Tech | 5 |
Enterprise Applications | 2 |
HealthTech | 2 |
Artificial Intelligence - Industry Applications | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Regeneron Ventures' Investments by Geography
Regeneron Ventures has made most investments in United States (13), followed by Belgium where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 13 |
Belgium | 1 |
Note: We have considered here, only first round of investments
Regeneron Ventures' recent investments
Regeneron Ventures has made 4 investments in 2026 so far. City Therapeutics and Coultreon are the latest among them.Here are the most recent investments by Regeneron Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Jun 08, 2026 | United States | Series B | 7403 | ||
Apr 28, 2026 | Belgium | Series A | 1289 | ||
Apr 13, 2026 | United States | Series B | 7550 | [+3] | |
Jan 20, 2026 | United States | Series A | 3353 | ||
Dec 21, 2025 | United States | Series B | 6331 | [+2] |
Team profile of Regeneron Ventures
Regeneron Ventures has a team of 2 members including 2 Partners located in United States. Regeneron Ventures' team does not sit on the board of any company as of now.Co-investors of Regeneron Ventures
Over the past 3 years, 136 investors have co-invested in Regeneron Ventures's portfolio companies. This includes funds and angels.
- Invested before Regeneron Ventures: Emerson Collective, Euclidean Capital and 66 others have invested in rounds before Regeneron Ventures. There are 2 companies where Emerson Collective has invested before Regeneron Ventures and 2 companies where Euclidean Capital has invested before Regeneron Ventures.
- Top Co-investors of Regeneron Ventures: 63 investors entered a company along with Regeneron Ventures. These include investors like Invus (3 companies).
- Invested after Regeneron Ventures: A total of 5 investors have invested in Regeneron Ventures's portfolio after their investments. Top Investors include Sofinnova Investments (1 company), Viking Global Investors (1 company) and Casdin Capital (1 company).
Recent News related to Regeneron Ventures
•
City Therapeutics Secures $99.5M Series B for RNAiVentureburn•Jun 09, 2026•City Therapeutics, NYBC Ventures, Regeneron Ventures, Rock Springs Capital and 6 others
•
Coultreon Biopharma Secures $125M Series A to Advance Immunology PipelineBioSpace•Apr 28, 2026•Novo Holdings, Forbion, Sofinnova Investments, Finchley Healthcare Ventures and 16 others
•
AP Neomorph Announces Closing of $100 Million Series B FinancingBakersfield•Apr 13, 2026•Deerfield, Regeneron Ventures, Neomorph, Longwood Fund and 2 others
•
Think Bioscience Raises $55M in Oversubscribed Series Aintelligence360•Feb 09, 2026•Regeneron Ventures, Think Bioscience, Buff Gold Ventures, CE Venture Capital and 4 others
•
Think Bioscience Raises $55M in Series A FundingFinSMEs•Jan 20, 2026•Regeneron Ventures, Think Bioscience, Buff Gold Ventures, CE Venture Capital and 5 others
•
Atavistik Bio Raises $120M in Series B FinancingFinSMEs•Dec 21, 2025•Nextech Invest, Lux Capital, Atavistik, Regeneron Ventures and 7 others
•
•
•
Zag Bio launches with $80M to train the immune system for better TregsEndpoints•Oct 28, 2025•T1D Fund, Polaris Partners, Zag Bio, Regeneron Ventures and 7 others
•
Strand Therapeutics raises $153M for ‘programmable’ mRNA drugs; Regeneron, Eli Lilly, and Amgen back the firmBioPharmaDive•Aug 08, 2025•Strand Therapeutics, Lilly, Regeneron Pharmaceuticals, Kinnevik and 12 others
